Ny data publiceras på ECTRIMS i Berlin på TECFIDERA (dimetylfumarat) och TYSABRI (natalizumab)

Ny data publiceras på ECTRIMS i Berlin på TECFIDERA (dimetylfumarat) och TYSABRI (natalizumab)

Biogen har definierat Real World Evidence som en viktig hjälp för att ta beslut i klinisk praxis och optimera omhändertagandet av patienter. Biogen fortsätter att utvärdera sin MS-behandlingar, dimetylfumarat och natalizumab för att bättre förstå fördelarna med att använda dessa behandlingar.

Results from the ENDORSE study demonstrate that the clinical benefits of dimethyl fumarate in reducing MS relapses and disability progression in newly diagnosed patients were maintained throughout nine years of continuous dimethyl fumarate treatment, with relapse rates remaining stable and more than 90 percent of patients maintaining walking abilities. An analysis from the natalizumab Observational Program (TOP), the largest ongoing, real-world study of natalizumab-treated patients, reinforces the long-term safety and consistent effectiveness of natalizumab over 10 years, especially for patients with minimal or mild disability and those who were previously treated with fewer disease-modifying therapies.

Featured data presentation details:

  • Temporal Relationship of Serum Neurofilament Light Levels and Radiological Disease Activity in Patients with Multiple Sclerosis – Poster P532 – Wednesday, 10 October, 17:00-19:00 CET
  • Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients: Is it Ready for Implementation into Clinical Care? – Platform 5 – Thursday, 11 October, 11:16-11:28 CET
  • Real-world Data from Over 10 years in the TYSABRI® Observational Program: Long-term Safety and Effectiveness of Natalizumab in Relapsing-remitting Multiple Sclerosis Patients – Poster P908 – Thursday, 11 October, 17:15-19:15 CET
  • Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis – Poster P920 – Thursday, 11 October, 17:15-19:15 CET


Läs hela pressreleasen